© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
In patients undergoing primary pterygium excision with conjunctival autografting, use of a fibrin tissue adhesive (Tisseel VH Fibrin Sealant) to adhere the graft can improve long-term outcomes by lowering recurrence rates, according to the findings of a retrospective case series presented by investigators from the University of California-Irvine.
In patients undergoing primary pterygium excision with conjunctival autografting, use of a fibrin tissue adhesive (Tisseel VH Fibrin Sealant) to adhere the graft can improve long-term outcomes by lowering recurrence rates, according to the findings of a retrospective case series presented by investigators from the University of California-Irvine.
The study compared recurrence rates in 27 eyes that had surgery using the tissue adhesive and a comparator group of 20 eyes in which the conjunctival autograft was secured using 8-0 Vicryl. All surgeries were performed by a single surgeon and received the same corticosteroid regimen postoperatively. The patients were predominantly non-Hispanic whites, and the two study groups were well matched with respect to demographic features and pterygium size.
During a minimum follow-up of 6 months, the recurrence rate was significantly lower in the tissue adhesive group compared with the sutured group, 3.7% versus 20%, respectively. All recurrences occurred within the first 3 to 3.5 months after surgery, and the patients who developed a recurrence were younger on average than those who remained recurrence-free.
"Our study found a lower rate of recurrence in a patient population that was predominantly white and residing in southern California," said Marjan Farid, MD. "However, it is a retrospective review and relatively small. Further studies are needed in larger sample sizes and should look at effects of the tissue adhesive in various racial-ethnic groups as well as when used in combination with amniotic membrane transplants or mitomycin-C."
Understanding the biological causes and cell types that lead to one of the leading causes of irreversible blindness worldwide could benefit treatment in patients
Aerie Pharmaceuticals doses first participant in COMET-2 study of dry eye candidate
Technology, people key to improving health outcomes, driving revenue